1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
2
|
Zhong JH, Li H, Xiao N, Ye XP, Ke Y, Wang
YY, Ma L, Chen J, You XM, Zhang ZY, et al: Hepatic resection is
safe and effective for patients with hepatocellular carcinoma and
portal hypertension. PloS One. 9:e1087552014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rahbari NN, Ulrich AB, Bruckner T, Münter
M, Nickles A, Contin P, Löffler T, Reissfelder C, Koch M, Büchler
MW and Weitz J: Surgery for locally recurrent rectal cancer in the
era of total mesorectal excision, Is there still a chance for cure?
Ann Surg. 253:522–533. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Takayama T: Surgical treatment for
hepatocellular carcinoma. Jpn J Clin Oncol. 41:447–454. 2011.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Nagai T, Arao T, Furuta K, et al:
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial
mesenchymal transition in hepatocellular carcinoma. Mol Cancer
Ther. 10:169–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Usami Y, Takaoka I, Ichikawa H, Horibe Y,
Tomiyama S, Ohtsuka M, Imanishi Y and Arimoto M: First total
synthesis of antitumor natural product (+)- and (−)-pericosine A,
Determination of absolute stereo structure. J Org Chem.
72:6127–6134. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs over the 30 years from 1981 to 2010. J Nat
Prod. 75:311–335. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Satooka H, Isobe T, Nitoda T and Kubo I:
Melanogenesis inhibitors from Rabdosia japonica.
Phytomedicine. 19:1016–1023. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Sun HD, Huang SX and Han QB: Diterpenoids
from Isodon species and their biological activities. Nat Prod Rep.
23:673–698. 2006. View
Article : Google Scholar : PubMed/NCBI
|
11
|
Kim BW, Koppula S, Hong SS, Jeon SB, Kwon
JH, Hwang BY, Park EJ and Choi DK: Regulation of microglia activity
by glaucocalyxin-A: Attenuation of lipopolysaccharide-stimulated
neuroinflammation through NF-κB and p38 MAPK signaling pathways.
PloS One. 8:e557922013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Xiao X, Cao W, Jiang X, Zhang W, Zhang Y,
Liu B, Cheng J, Huang H, Huo J and Zhang X: Glaucocalyxin A, a
negative Akt regulator, specifically induces apoptosis in human
brain glioblastoma U87MG cells. Acta Biochim Biophys Sin
(Shanghai). 45:946–952. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang B and Long K: Effects of
glaucocalyxin A on aggregation and cAMP levels of rabbit platelets
in vitro. Zhongguo Yao Li Xue Bao. 14:347–350.
1993.PubMed/NCBI
|
14
|
Liu MJ, Sun Q, Yu LJ, Bao GL and Zhao M:
Protective effect of glaucocalyxin A inhibits H2O2-induced H9c2
cardiomyocytes injury. Latin American J Pharmacy. 33:1216–1220.
2014.
|
15
|
Gao LW, Zhang J, Yang WH, Wang B and Wang
JW: Glaucocalyxin A induces apoptosis in human leukemia HL-60 cells
through mitochondria-mediated death pathway. Toxicol In Vitro.
25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yang WH, Zhang Z, Sima YH, Zhang J and
Wang JW: Glaucocalyxin A and B-induced cell death is related to GSH
perturbation in human leukemia HL-60 cells. Anticancer Agents Med
Chem. 13:1280–1290. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Liu Q, Wang X, Zhang Y, Li CJ, Hu LH and
Shen X: Leukamenin F suppresses liver fibrogenesis by inhibiting
both hepatic stellate cell proliferation and extracellular matrix
production. Acta Pharmacol Sin. 31:839–848. 2010. View Article : Google Scholar : PubMed/NCBI
|
18
|
Ying N, Xu CL, Zhang J, Fu Q and Ma SP:
The effects of glaucocalyxin A in hepatic cancer HepG2 cell line.
Strait Pharm J. 24:235–238. 2012.
|
19
|
Wigmore PM, Mustafa S, El-Beltagy M, Lyons
L, Umka J and Bennett G: Effects of 5-FU. Adv Exp Med Biol.
678:157–164. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Fuji K, Node M, Ito N, Fujita E, Takeda S
and Unemi N: Terpenoids L. antitumor-activity of diterpenoids from
Rabdosia shikokiana var. occidentalis. Chem Pharm Bull.
33:1038–1042. 1985. View Article : Google Scholar
|
21
|
Takeda Y, Fujita T and Ueno A: Structures
Of Leukamenins. Chem Lett. 10:1229–1232. 1981. View Article : Google Scholar
|
22
|
Ding L, Hou Q, Zhou Q, Zhang Q, Hou T and
Liu G: Structure-activity relationships of eight ent-kaurene
diterpenoids from three Isodon plants. Res Chem Intermed.
36:443–452. 2010. View Article : Google Scholar
|
23
|
Yang J, Liu Y, Xue C, Yu W, Zhang J and
Qiao C: Synthesis and biological evaluation of glaucocalyxin A
derivatives as potential anticancer agents. Eur J Med Chem.
86:235–241. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Morales A, Pérez P, Mendoza R, Compagnone
R, Suarez AI, Arvelo F, Ramírez JL and Galindo-Castro I: Cytotoxic
and proapoptotic activity of ent-16beta-17alpha-dihydroxykaurane on
human mammary carcinoma cell line MCF-7. Cancer Lett. 218:109–116.
2005. View Article : Google Scholar : PubMed/NCBI
|
25
|
Geng S, Sun B, Lu R and Wang J: Coleusin
factor, a novel anticancer diterpenoid, inhibits osteosarcoma
growth by inducing bone morphogenetic protein-2-dependent
differentiation. Mol Cancer Ther. 13:1431–1441. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang X: The expanding role of mitochondria
in apoptosis. Genes Dev. 15:2922–2933. 2001.PubMed/NCBI
|
27
|
Park MT and Lee SJ: Cell cycle and cancer.
J Biochem Mol Biol. 36:60–65. 2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Buolamwini JK: Cell cycle molecular
targets in novel anticancer drug discovery. Curr Pharm Des.
6:379–392. 2000. View Article : Google Scholar : PubMed/NCBI
|